肝源性腹泻62例诊治分析

Objective To investigate the pathogenesis, diagnostic keys, and treatment of hepatogenous diarrhea. MethodsSixty-two patients with hepatogenous diarrhea were assigned to three levels of treatment. Patients given level-one treatment received live combined Clostridium butyricum and Bifidobacterium pow...

Full description

Bibliographic Details
Main Author: BAO Suxia
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Hepatology 2014-06-01
Series:Linchuang Gandanbing Zazhi
Subjects:
Online Access:http://www.lcgdbzz.org/qk_content.asp?id=5904&ClassID=424141243
id doaj-04ff288be76d4a96971a2591a044b332
record_format Article
spelling doaj-04ff288be76d4a96971a2591a044b3322020-11-24T23:04:41ZzhoEditorial Department of Journal of Clinical HepatologyLinchuang Gandanbing Zazhi1001-52561001-52562014-06-0130656056210.3969/j.issn.1001-5256.2014.06.021肝源性腹泻62例诊治分析BAO Suxia0Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou UniversityObjective To investigate the pathogenesis, diagnostic keys, and treatment of hepatogenous diarrhea. MethodsSixty-two patients with hepatogenous diarrhea were assigned to three levels of treatment. Patients given level-one treatment received live combined Clostridium butyricum and Bifidobacterium powder for regulating intestinal flora; patients given level-two treatment received montmorillonite powder for constriction, adsorption, and stopping diarrhea and compound diphenoxylate for inhibiting intestinal peristalsis; patients given level-three treatment received somatostatin for reducing portal pressure. Total bilirubin, albumin, total bile acid, prothrombin time, platelet count, spleen thickness, spleen length, splenic vein width, and portal vein width, as well as routine stool test and stool culture, were measured before treatment, and the times of diarrhea and time of onset were determined before and after treatment. Measurement data were expressed as P50(P25-P75), and statistical analysis was performed using the Spearman rank correlation coefficient. ResultsHepatogenous diarrhea was mostly seen in patients with decompensated liver cirrhosis. The higher the Child-Pugh score, the severer the diarrhea and the higher the susceptibility to diarrhea. Hepatogenous diarrhea had no specific clinical manifestations. Mild or moderate diarrhea was treated mainly by improving liver function, regulating intestinal flora, and inhibiting intestinal peristalsis, while severe diarrhea mainly by reducing portal pressure. ConclusionThe pathogenesis of hepatogenous diarrhea is complex, without specificity for the diagnosis. The key to therapy is to treat the primary liver disease, regulate intestinal flora, reduce portal pressure, and somatostatin shows good efficacy for severe diarrhea.http://www.lcgdbzz.org/qk_content.asp?id=5904&ClassID=424141243liver diseases; diarrhea; hypertensionportal; somatostatin
collection DOAJ
language zho
format Article
sources DOAJ
author BAO Suxia
spellingShingle BAO Suxia
肝源性腹泻62例诊治分析
Linchuang Gandanbing Zazhi
liver diseases; diarrhea; hypertension
portal; somatostatin
author_facet BAO Suxia
author_sort BAO Suxia
title 肝源性腹泻62例诊治分析
title_short 肝源性腹泻62例诊治分析
title_full 肝源性腹泻62例诊治分析
title_fullStr 肝源性腹泻62例诊治分析
title_full_unstemmed 肝源性腹泻62例诊治分析
title_sort 肝源性腹泻62例诊治分析
publisher Editorial Department of Journal of Clinical Hepatology
series Linchuang Gandanbing Zazhi
issn 1001-5256
1001-5256
publishDate 2014-06-01
description Objective To investigate the pathogenesis, diagnostic keys, and treatment of hepatogenous diarrhea. MethodsSixty-two patients with hepatogenous diarrhea were assigned to three levels of treatment. Patients given level-one treatment received live combined Clostridium butyricum and Bifidobacterium powder for regulating intestinal flora; patients given level-two treatment received montmorillonite powder for constriction, adsorption, and stopping diarrhea and compound diphenoxylate for inhibiting intestinal peristalsis; patients given level-three treatment received somatostatin for reducing portal pressure. Total bilirubin, albumin, total bile acid, prothrombin time, platelet count, spleen thickness, spleen length, splenic vein width, and portal vein width, as well as routine stool test and stool culture, were measured before treatment, and the times of diarrhea and time of onset were determined before and after treatment. Measurement data were expressed as P50(P25-P75), and statistical analysis was performed using the Spearman rank correlation coefficient. ResultsHepatogenous diarrhea was mostly seen in patients with decompensated liver cirrhosis. The higher the Child-Pugh score, the severer the diarrhea and the higher the susceptibility to diarrhea. Hepatogenous diarrhea had no specific clinical manifestations. Mild or moderate diarrhea was treated mainly by improving liver function, regulating intestinal flora, and inhibiting intestinal peristalsis, while severe diarrhea mainly by reducing portal pressure. ConclusionThe pathogenesis of hepatogenous diarrhea is complex, without specificity for the diagnosis. The key to therapy is to treat the primary liver disease, regulate intestinal flora, reduce portal pressure, and somatostatin shows good efficacy for severe diarrhea.
topic liver diseases; diarrhea; hypertension
portal; somatostatin
url http://www.lcgdbzz.org/qk_content.asp?id=5904&ClassID=424141243
work_keys_str_mv AT baosuxia gānyuánxìngfùxiè62lìzhěnzhìfēnxī
_version_ 1725629059920035840